Postmenopausal Osteoporosis Drug Found Safe in Long-Term Trial

by Bidita Debnath on  March 19, 2017 at 11:14 PM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

Study provides reassuring information about the short-term and long-term safety of denosumab, a monoclonal antibody that is used to treat postmenopausal osteoporosis.
 Postmenopausal Osteoporosis Drug Found Safe in Long-Term Trial
Postmenopausal Osteoporosis Drug Found Safe in Long-Term Trial

Adverse events that had been noted in a pivotal clinical trial in women age 60 to 90 years old treated for 3 years showed no tendency to increase after a further 3 years of treatment, the study showed.

In addition, women who crossed over from 3 years of placebo to 3 years of denosumab experienced no increase in adverse effects compared with women treated for the initial 3 years.

"All of this is consistent with an excellent safety and tolerability profile for denosumab treatment for osteoporosis," said Dr. Nelson Watts, lead author of the study results published in Journal of Bone and Mineral Research. The authors noted that, especially in older women on long-term treatment, many if not all adverse events could be called "life events" -- things that would have happened whether or not the person was participating in a clinical trial.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Fracture Rickets Osteoporosis Menopause Lifestyle And Osteoporosis Dilatation and Curettage Kyphosis Signature Drug Toxicity Colle’s Fracture 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...